Advertisement

Topics

Crucell N.V Company Profile

07:17 EDT 23rd March 2019 | BioPortfolio

Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global biopharmaceutical company focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. In 2009 alone, Crucell distributed more than 115 million vaccine doses in more than 100 countries around the world, with the fast majority of doses (97%) going to developing countries. Crucell is one of the major suppliers of vaccines to UNICEF and the developing world. Crucell was the first manufacturer to launch a fully-liquid pentavalent vaccine called Quinvaxem(R). Quinvaxem(R) protects against five important childhood diseases and over 130 million doses have been sold since its launch in 2006 in more than 50 GAVI countries. Through Quinvaxem(R) and its innovation, Crucell has become a major partner in protecting children in developing countries. Crucell's core portfolio also includes a vaccine against hepatitis B and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as an oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6(R) production technology. The Company licenses its PER.C6(R) technology and other technologies to the biopharmaceutical industry. Important partners and licensees include Johnson & Johnson, DSM Biologics, sanofi-aventis, Novartis, Wyeth, GSK, CSL and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Argentina, China, Italy, Korea, Spain, Sweden, Switzerland, UK and the USA. The Company employs over 1200 people. For more information, please visit http://www.crucell.com.


News Articles [3 Associated News Articles listed on BioPortfolio]

PTV News: Sep 28, 2009

Top stories on September 28th, 2009: Abbott buys Solvay's pharma unit J&J enter flu vaccine fray with stake in Crucell Novo Nordisk to expand workforce in India Januvia and Janumet get EMA t...

Global Hepatitis A Vaccine Market Status and Outlook 20182025 [Report Updated: 15082018] Prices from USD $4000

Report SnapshotKey Content of Chapters Including and can be customized, report is a semifinished version, and it takes 4872 hours to upgradePart 1:Terminology Definition, Industry Chain,Industry Dynam...

Global H3N2 Infection Treatment Market Status and Outlook 20182025 [Report Updated: 19082018] Prices from USD $4000

Report SnapshotKey Content of Chapters Including and can be customized, report is a semifinished version, and it takes 4872 hours to upgradePart 1:Terminology Definition, Industry Chain,Industry Dynam...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV

This is a clinical trial in which healthy volunteers will be administered two experimental Ebola vaccines: ChAd3-EBO-Z and Ad26.ZEBOV. Four groups of volunteers will be vaccinated with bot...

Companies [7 Associated Companies listed on BioPortfolio]

Crucell

Crucell discovers and develops fully human biopharmaceuticals that utilize the immune system to combat disease. Crucell’s proprietary technology platforms, MAbstract™ , AdVac™ and PER.C6™ , en...

Crucell N.V

Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global biopharmaceutical company focused on research development, production and marketing of vaccines, proteins and antibodies...

BaseClea

BaseClear strives for excellence in DNA services and products. This dedication to quality and superior service has lead to a steady development and growth. BaseClear now offers a full, coherent range ...

Pevion Biotech AG

Pevion Biotech AG is a fully independent Swiss vaccine company that develops innovative vaccines for unmet medical needs based on its clinically and commercially validated virosome technology. Its p...

Forbion Capital Partners

Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing hi...

More Information about "Crucell N.V" on BioPortfolio

We have published hundreds of Crucell N.V news stories on BioPortfolio along with dozens of Crucell N.V Clinical Trials and PubMed Articles about Crucell N.V for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Crucell N.V Companies in our database. You can also find out about relevant Crucell N.V Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Vaccines
A vaccine is any preparation intended to produce immunity to a disease by stimulating the production of antibodies. It creates immunity but does not cause the disease. There are several differnt types of vaccine avalable; Killed microorganisms; which s...


Corporate Database Quicklinks



Searches Linking to this Company Record